Breaking News Instant updates and real-time market news.

SOGO

Sogou

$11.81

0.375 (3.28%)

, AMAG

Amag Pharmaceuticals

$13.95

-0.4 (-2.79%)

10:33
12/07/17
12/07
10:33
12/07/17
10:33

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sogou (SOGO) initiated with an Overweight at JPMorgan. 2. Amag Pharmaceuticals (AMAG) initiated with a Neutral at B. Riley FBR. 3. Akebia (AKBA) initiated with a Buy at BTIG. 4. Synnex (SNX) initiated with a Buy at SunTrust. 5. Cancer Genetics (CGIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

SOGO

Sogou

$11.81

0.375 (3.28%)

AMAG

Amag Pharmaceuticals

$13.95

-0.4 (-2.79%)

AKBA

Akebia

$15.40

0.21 (1.38%)

SNX

Synnex

$131.37

0.69 (0.53%)

CGIX

Cancer Genetics

$2.15

(0.00%)

  • 02

    Feb

  • 14

    Feb

SOGO Sogou
$11.81

0.375 (3.28%)

12/07/17
JPMS
12/07/17
INITIATION
Target $17
JPMS
Overweight
Sogou initiated with an Overweight at JPMorgan
JPMorgan analyst Alex Yao started Sogou with an Overweight rating and $17 price target. The company is the fastest growing search engine globally, and can accelerate traffic share and earnings growth through its Tencent-WeChat partnership, the analyst contends.
12/04/17
FBCO
12/04/17
INITIATION
Target $16.3
FBCO
Outperform
Sogou initiated with an Outperform at Credit Suisse
Credit Suisse analyst Thomas Chong started Sogou with an Outperform rating and $16.30 price target. As one of China's leading search engines in PC and mobile, the analyst expects Sogou to "ride the secular search ad industry trend."
AMAG Amag Pharmaceuticals
$13.95

-0.4 (-2.79%)

10/23/17
JANY
10/23/17
NO CHANGE
JANY
Neutral
Antares CRL doesn't raise issues for Amag Pharmaceuticals, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA complete response letter issued to Antares (ATRS) for Xyosted did not pertain to the Quickshot subcutaneous autoinjector, which raises his confidence the FDA will not identify such issues as a short coming of the sNDA for Amag Pharmaceuticals' (AMAG) Makena SQ. However, he keeps a Neutral rating on Amag shares, noting that the primary uncertainty for the sNDA for Makena SQ is the fact that its peak plasma levels is higher than the upper bound the FDA uses to define bioequivalence.
11/02/17
PIPR
11/02/17
NO CHANGE
Target $16
PIPR
Neutral
Piper calls Amag's Makena write-down a 'head-scratcher'
Piper Jaffray analyst Christopher Raymond calls Amag Pharmaceuticals' $319M Makena-related intangible asset write-down a "head-scratcher." The write-down indicates a deteriorating long-term view of the franchise, Raymond tells investors in a research note. The analyst, who admits he still doesn't understand the logic behind the move, lowered his price target for Amag shares to $16 from $18. He keeps a Neutral rating on the name.
11/06/17
JEFF
11/06/17
NO CHANGE
Target $16
JEFF
Buy
Amag Pharmaceuticals price target lowered to $16 from $34 at Jefferies
Jefferies analyst Eun Yang lowered her price target for Amag Pharmaceuticals to $16 citing the company's "disappointing" Q3 results and lowered lowered guidance. The analyst keeps a Buy rating on the shares, however, saying the shares at current levels reflect little expectation for the company.
12/07/17
RILY
12/07/17
INITIATION
Target $16
RILY
Neutral
Amag Pharmaceuticals initiated with a Neutral at B. Riley FBR
B. Riley FBR started Amag Pharmaceuticals with a Neutral rating and $16 price target.
AKBA Akebia
$15.40

0.21 (1.38%)

11/15/17
HCWC
11/15/17
NO CHANGE
Target $24
HCWC
Buy
Akebia recent selloff not based on fundamentals, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce notes that since the close on November 8, shares of FibroGen (FGEN) are down 17% while Akebia Therapeutics (AKBA) is down 21.3%. He attributes some of the weakness to FibroGen's Q3 earnings call, in which concerns arose that cardiovascular events in the large Phase 3 roxadustat cardiovascular outcomes trials are accruing too slowly. The analyst believes this has no fundamental bearing on Akebia or vadadustat, however. He keeps a Buy rating on the shares with a $24 price target.
09/14/17
RBCM
09/14/17
INITIATION
Target $17
RBCM
Sector Perform
Akebia initiated with a Sector Perform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Akebia with a Sector Perform and a $17 price target.
12/07/17
BTIG
12/07/17
INITIATION
Target $30
BTIG
Buy
Akebia initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Akebia with a Buy rating and a price target of $30. Hazlett says the company's development of Vadadustat - an HIF-PH inhibitor for anemia secondary to chronic kidney disease - has the potential to attain "hemoglobin control with material advantages compared to current standard-of-care injectable erythropoiesis stimulating agents". With its development partnerships in Japan and EU, the treatment is in a Phase 3 program expected for readouts in the first half of 2019.
10/04/17
MZHO
10/04/17
INITIATION
MZHO
Buy
Akebia initiated with a Buy at Mizuho
SNX Synnex
$131.37

0.69 (0.53%)

09/18/17
NEED
09/18/17
INITIATION
NEED
Buy
Synnex coverage resumed with a Buy at Needham
Needham analyst Sean Hannan resumed coverage of Synnex with a $135 price target and a Buy rating. The analyst says that the company is benefiting from "healthy IT spending trends," including strong data center and cloud activity. He believes that its acquisition of Westcon-Comstor should boost its offering and geographic position. He calls the company "an attractive name possessing high-quality execution, a diversified business, and an improving model through strategic M&A. "
09/26/17
NEED
09/26/17
NO CHANGE
NEED
Synnex price target raised to $145 from $135 at Needham
Needham analyst Sean K.F. Hannan raised his price target on Synnex after the company reported beat and raise results. Calling the results "very healthy," the analyst says that the company is executing well, and he has become more upbeat about its acquisition of Westcon-Comstor. He keeps a Buy rating on the shares.
10/06/17
PIVT
10/06/17
INITIATION
Target $138
PIVT
Hold
Synnex initiated with a Hold at Pivotal Research
Pivotal Research analyst Lou Miscioscia initiated Synnex with a Hold and $138 price target saying he would wait for a better entry point.
12/07/17
RHCO
12/07/17
INITIATION
Target $145
RHCO
Buy
Synnex initiated with a Buy at SunTrust
SunTrust analyst Frank Atkins initiated Synnex with a Buy rating and a price target of $145, saying the company offers a "unique blended model of both technology distribution and business process management". Atkins notes that the much higher margins of the Concentrix segment is underappreciated by the street, also adding that the company's management brings a track record of operational excellence, above-industry growth, and margin expansion.
CGIX Cancer Genetics
$2.15

(0.00%)

12/07/17
MAXM
12/07/17
INITIATION
Target $6
MAXM
Buy
Cancer Genetics initiated with a Buy at Maxim
Maxim analyst Jason McCarthy initiated Cancer Genetics with a Buy rating and a price target of $6, calling the company "an emerging player in oncology testing, from discovery to commercialization". McCarthy says Cancer Genetics is leading a shift in oncology toward immune therapy, supporting over 200 clinical trials with tests and services. The analyst notes that the company is on track to generate $30M in revenue this year while growing its biopharma partnerships, adding that Cancer Genetics is likely ahead of the curve and "ideally positioned" to be a part of both biopharma and patient diagnostics expansion.
06/26/17
BNCH
06/26/17
INITIATION
Target $6
BNCH
Speculative Buy
Cancer Genetics initiated with a Speculative Buy at Benchmark
Benchmark analyst Raymond Myers started Cancer Genetics with a Speculative Buy rating and $6 price target.

TODAY'S FREE FLY STORIES

ADSK

Autodesk

$122.99

-2.76 (-2.19%)

16:27
11/20/18
11/20
16:27
11/20/18
16:27
Hot Stocks
Breaking Hot Stocks news story on Autodesk »

Autodesk up 8% to $133.23…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

  • 04

    Dec

HOLX

Hologic

$41.29

-0.29 (-0.70%)

16:23
11/20/18
11/20
16:23
11/20/18
16:23
Hot Stocks
Hologic VP Allison Bebo sells 6,500 shares of company stock »

Hologic VP Allison Bebo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 30

    Nov

CAL

Caleres

$30.93

-1.165 (-3.63%)

16:23
11/20/18
11/20
16:23
11/20/18
16:23
Earnings
Caleres lowers FY18 adj. EPS view to $2.25-$2.35 from $2.40-$2.50 »

Consensus $2.46. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

K

Kellogg

$61.72

0.03 (0.05%)

16:22
11/20/18
11/20
16:22
11/20/18
16:22
Hot Stocks
Kellogg CFO acquires 8,190 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

FLR

Fluor

$41.39

-2.26 (-5.18%)

16:20
11/20/18
11/20
16:20
11/20/18
16:20
Hot Stocks
Fluor selected for lithium, boron mine project in Nevada »

Fluor Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

TGT

Target

$69.05

-8.08 (-10.48%)

, BBY

Best Buy

$63.54

1.35 (2.17%)

16:20
11/20/18
11/20
16:20
11/20/18
16:20
OnTheFly
Fly Intel: Wall Street's top stories for Tuesday »

Stocks began the session…

TGT

Target

$69.05

-8.08 (-10.48%)

BBY

Best Buy

$63.54

1.35 (2.17%)

CPB

Campbell Soup

$40.57

2.1 (5.46%)

KLIC

Kulicke & Soffa

$21.25

1.345 (6.76%)

A

Agilent

$67.61

5.04 (8.06%)

LIVN

LivaNova

$98.00

-22.28 (-18.52%)

LB

L Brands

$28.43

-6.105 (-17.68%)

AAPL

Apple

$177.10

-8.7 (-4.68%)

BSX

Boston Scientific

$34.05

-1.24 (-3.51%)

NAVI

Navient

$10.74

-1.255 (-10.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 27

    Nov

  • 29

    Nov

  • 04

    Dec

  • 05

    Dec

  • 11

    Dec

  • 03

    Mar

USAT

USA Technologies

$4.96

-0.055 (-1.10%)

16:20
11/20/18
11/20
16:20
11/20/18
16:20
Hot Stocks
USA Technologies provides update on Nasdaq notification of deficiency »

USA Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
11/20/18
11/20
16:20
11/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for November 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMK

GenMark

$5.01

(0.00%)

16:19
11/20/18
11/20
16:19
11/20/18
16:19
Syndicate
Breaking Syndicate news story on GenMark »

GenMark files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

CAL

Caleres

$30.93

-1.165 (-3.63%)

16:18
11/20/18
11/20
16:18
11/20/18
16:18
Earnings
Caleres reports Q3 adj. EPS 81c, consensus 88c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

RMBL

RumbleON

$5.76

-0.35 (-5.73%)

16:18
11/20/18
11/20
16:18
11/20/18
16:18
Syndicate
Breaking Syndicate news story on RumbleON »

RumbleON files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 10

    Dec

GPS

Gap

$24.65

-0.79 (-3.11%)

16:18
11/20/18
11/20
16:18
11/20/18
16:18
Earnings
Gap narrows FY18 EPS view to $2.55-$2.60 from $2.55-$2.70, consensus $2.56 »

Backs FY18 SSS view of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

MRCY

Mercury Systems

$46.80

-0.48 (-1.02%)

16:18
11/20/18
11/20
16:18
11/20/18
16:18
Hot Stocks
Mercury Systems gets $6.7M Integrated subsystems order for naval electronics »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRI

Thomson Reuters

$47.83

-0.59 (-1.22%)

16:17
11/20/18
11/20
16:17
11/20/18
16:17
Hot Stocks
Thomson Reuters receives court approval for return of capital transaction »

Thomson Reuters announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

STRM

Streamline Health

$0.90

(0.00%)

, WFC

Wells Fargo

$52.54

-0.77 (-1.44%)

16:17
11/20/18
11/20
16:17
11/20/18
16:17
Hot Stocks
Streamline Health extends banking agreement with Wells Fargo into 2020 »

Streamline Health…

STRM

Streamline Health

$0.90

(0.00%)

WFC

Wells Fargo

$52.54

-0.77 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
11/20/18
11/20
16:17
11/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$24.65

-0.79 (-3.11%)

16:16
11/20/18
11/20
16:16
11/20/18
16:16
Earnings
Gap reports Q3 EPS 69c, consensus 68c »

Reports Q3 revenue $4.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
11/20/18
11/20
16:16
11/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.10

-2.69 (-5.51%)

16:14
11/20/18
11/20
16:14
11/20/18
16:14
Hot Stocks
Breaking Hot Stocks news story on Foot Locker »

Foot Locker up 11% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BJ

BJ's Wholesale

$19.85

-0.22 (-1.10%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Hot Stocks
Breaking Hot Stocks news story on BJ's Wholesale »

BJ's Wholesale now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

FL

Foot Locker

$46.05

-2.74 (-5.62%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Hot Stocks
Foot Locker CFO says 'encouraged' by Q3 SSS growth »

"We're…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

HTBX

Heat Biologics

$2.04

0.14 (7.37%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Syndicate
Heat Biologics fiels to sell common stock and warrants, no amount given »

A.G.P./Alliance Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.14

-2.65 (-5.43%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Hot Stocks
Foot Locker reports merchandise inventories $1.305B at November 3 »

As of November 3, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TWI

Titan International

$6.51

-0.4 (-5.79%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Hot Stocks
Titan International receives settlement put option notice »

Titan International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$33.93

-0.69 (-1.99%)

16:12
11/20/18
11/20
16:12
11/20/18
16:12
Hot Stocks
Mylan announces voluntary recall of select lots of Valsartan-containing products »

Mylan announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.